Pedro Isaacsson

Medical Oncologist at Johns Hopkins Hospital - Clinical & Research Postdoctoral Fellowship Genitourinary cancers.

[Denis Jardim @jardim_denis]

It is a pleasure to continue contributing to @LACOG_group with this Great Team
@diogodrigues @drdanielvargas @fedelosco @PedroIsaacsson

[Eric Feigl-Ding @DrEricDing]

HORRIFYING #COVID19 death curve in one of wealthiest cities in Brazil— Porto Alegre is capital of Rio Grande do Sul— with many top-notch hospitals with better rating than most US🏥. And their health system still collapsed under #P1.

Imagine now rest of 🇧🇷.

(HT @alexaguiarpoa)

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Results reinforce my confidence in IOs in #ProstateCancer 👉🏻 Finally OS (pre-specified endpoint) is significantly higher with IPI in postdocetaxel mCRPC, in a phase 3 trial we started 10 yrs ago under #KarimFizazi leadership. https://t.co/z9CAa9TeEu @OncoAlert Thanks @EUplatinum

[Mark C. Markowski @MarkowskiGUOnc]

When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. Wonderful summary of parpi use in prostate cancer. Well done ⁦@EAntonarakis⁩ #pcsm https://t.co/JBjFAdblFi

[European Urology @EUplatinum]

Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer
@umangtalking @neerajaiims @OncHahn @DrVaishampayan
https://t.co/iko7TRyZmv

[Pedro Isaacsson @PedroIsaacsson]

@MarkowskiGUOnc 👏🏻👏🏻

[Sumanta K. Pal, MD, FASCO @montypal]

Just out in @EUplatinum - @umangtalking @huntsmancancer (mentored by @neerajaiims) works with @EAntonarakis @AlvaAjjai @DrVaishampayan @OncHahn @maughanonc to demonstrate that mtSPOP confers superior PFS/OS in mCSPC (prev shown in mCRPC). Full article at: https://t.co/lbdl65GWTm

[Arjun Gupta @guptaarjun90]

The great @DrArsenOsipov, Chief Fellow at @HopkinsMedicine #Oncology, advises Research Fellows at his graduation talk.
Have learnt a tremendous amount from him the last 2 years. Fabulous peer mentor to me, and dozens of us! Will miss you, brother.
cc: @kamarrone

[Journal of Clinical Oncology @JCO_ASCO]

CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies & Immune Checkpoint Blockade https://t.co/mbHmRsPzGT #pcsm #JCOPO

[Journal of Clinical Oncology @JCO_ASCO]

CDK12-Altered Prostate Cancer: Clinical Features & Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, & PD-1 Inhibitors https://t.co/BN6wpmobHd #pcsm #JCOPO

[Pedro Isaacsson @PedroIsaacsson]

@ramsedhom @JOP_ASCO @guptaarjun90 @mrmessmer @josephcmurray @tsmit136 @ASCO_pubs @ASCO @fischmd @rabrazzak @tomleblancMD Superstars! Congrats!

[Neeraj Agarwal, MD, FASCO @neerajaiims]

CDK12 altered metastatic prostate cancer: suboptimal response to abi/enza, taxanes or PARP inhibitors but encouraging signal on Rx with PD-1/L1i. Honored to be a part of this wonderful multi-center effort led by @EAntonarakis @ASCO_pubs @JCOPO_ASCO Time for a randomized trial.

[PCF Science @PCF_Science]

Two papers + editorial on #ProstateCancer with bi-allelic CDK12-loss: clinical features & therapeutic responses including to checkpoint #immunotherapy.
#PCFfunded @PCFnews @EAntonarakis @AlvaAjjai @xiaoweimd
https://t.co/K53qMFcIVL
https://t.co/EJ2uXVysj0
https://t.co/ntDVmyuSYL

[Panagiotis Vlachostergios @Panos_Vlach]

Lots of interest for CDK12-altered #prostatecancer @JCOPO_ASCO @ASCO_pubs.2multictr #PrecisionMedicine works on responses2standard tx, #Immunotherapy @EAntonarakis @neerajaiims @DrScottTagawa @cnsternberg,R.Dreicer,O.Sartor,M.Hussain.https://t.co/gUb8JHKy17

[Pedro Isaacsson @PedroIsaacsson]

@AdrianaHepner @ASCO 👏🏻👏🏻

[Pedro Isaacsson @PedroIsaacsson]

@veramagalhaes CNPJ? Por que não CLT?

[ASCO @ASCO]

We're proud to partner w/ @FDAOncology & @CancerResrch on this impt work that will allow more ppl to participate in #ClinicalTrials

[Johns Hopkins Medicine @HopkinsMedicine]

#Cancer in the lead – but not for long. Certain proteins help cancer cells thrive, but we may be able to eliminate that advantage.

[Denis Wirtz @deniswirtz]

The economic impact of @JohnsHopkins:

Hopkins is Maryland’s largest employer, a major purchaser of goods and services, a sponsor of construction projects and a magnet for students and visitors.

In FY17, Hopkins accounted for >$12 billion in economic output and 105,800 jobs.

[Ali Khaki @arkhaki]

Thanks to mentors and collaborators!
@PGrivasMDPhD @ShankaranVeena @gary_lyman @sonpavde @MattGalsky @bilenma @AbhiTrip87 @PedroIsaacsson @PBarataMD @LDiamantMD @MonikaJoshimd @ZakhariaYousef